DK1641787T3 - Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister - Google Patents

Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister

Info

Publication number
DK1641787T3
DK1641787T3 DK04740230T DK04740230T DK1641787T3 DK 1641787 T3 DK1641787 T3 DK 1641787T3 DK 04740230 T DK04740230 T DK 04740230T DK 04740230 T DK04740230 T DK 04740230T DK 1641787 T3 DK1641787 T3 DK 1641787T3
Authority
DK
Denmark
Prior art keywords
oxytocin antagonists
substituted diketopiperazines
diketopiperazines
substituted
oxytocin
Prior art date
Application number
DK04740230T
Other languages
Danish (da)
English (en)
Inventor
John Liddle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1641787T3 publication Critical patent/DK1641787T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK04740230T 2003-06-24 2004-06-22 Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister DK1641787T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314738A GB0314738D0 (en) 2003-06-24 2003-06-24 Novel compounds
PCT/EP2004/006814 WO2005000840A1 (en) 2003-06-24 2004-06-22 Substituted diketopiperazines and their use as oxytocin antagonists

Publications (1)

Publication Number Publication Date
DK1641787T3 true DK1641787T3 (da) 2007-09-17

Family

ID=27637257

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740230T DK1641787T3 (da) 2003-06-24 2004-06-22 Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister

Country Status (31)

Country Link
US (6) US8071594B2 (xx)
EP (1) EP1641787B1 (xx)
JP (1) JP5128126B2 (xx)
KR (1) KR101131378B1 (xx)
CN (2) CN100404532C (xx)
AR (1) AR044869A1 (xx)
AT (1) ATE361295T1 (xx)
AU (1) AU2004251868B2 (xx)
BR (1) BRPI0411729A (xx)
CA (1) CA2530310C (xx)
CY (1) CY1107703T1 (xx)
DE (1) DE602004006268T2 (xx)
DK (1) DK1641787T3 (xx)
EG (1) EG24929A (xx)
ES (1) ES2285474T3 (xx)
GB (1) GB0314738D0 (xx)
HK (1) HK1088910A1 (xx)
HR (1) HRP20070286T3 (xx)
IL (1) IL172529A (xx)
IS (1) IS2463B (xx)
MA (1) MA27887A1 (xx)
MX (1) MXPA05014068A (xx)
MY (1) MY140653A (xx)
NO (1) NO332677B1 (xx)
NZ (1) NZ544006A (xx)
PL (1) PL1641787T3 (xx)
PT (1) PT1641787E (xx)
RU (1) RU2343152C2 (xx)
TW (1) TWI340745B (xx)
WO (1) WO2005000840A1 (xx)
ZA (1) ZA200509890B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
KR20170029507A (ko) 2014-06-16 2017-03-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조기 진통의 치료를 위한 레토시반
LT3397622T (lt) 2016-01-04 2022-06-27 ObsEva S.A. Hidroksipropiltiazolidino karboksamido darinio alfa-amino esterio ir tokolitinio agento įvedimas kartu
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN106674031A (zh) * 2016-11-18 2017-05-17 浙江工业大学 R‑2‑二氢茚氨酸的制备方法
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US20030229001A1 (en) 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
US9757424B2 (en) 2011-09-27 2017-09-12 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas

Also Published As

Publication number Publication date
HK1088910A1 (en) 2006-11-17
RU2343152C2 (ru) 2009-01-10
MXPA05014068A (es) 2006-03-02
ES2285474T3 (es) 2007-11-16
JP5128126B2 (ja) 2013-01-23
AU2004251868B2 (en) 2009-01-22
IL172529A0 (en) 2006-04-10
WO2005000840A8 (en) 2005-05-19
US8937179B2 (en) 2015-01-20
TWI340745B (en) 2011-04-21
CN1812987A (zh) 2006-08-02
NO20060383L (no) 2006-01-24
GB0314738D0 (en) 2003-07-30
ATE361295T1 (de) 2007-05-15
NO332677B1 (no) 2012-12-03
US20140058105A1 (en) 2014-02-27
MA27887A1 (fr) 2006-05-02
NZ544006A (en) 2008-12-24
US20130102783A1 (en) 2013-04-25
ZA200509890B (en) 2006-07-26
AR044869A1 (es) 2005-10-05
US20120004229A1 (en) 2012-01-05
CA2530310C (en) 2012-01-03
CN100404532C (zh) 2008-07-23
EP1641787A1 (en) 2006-04-05
MY140653A (en) 2010-01-15
AU2004251868A1 (en) 2005-01-06
WO2005000840A1 (en) 2005-01-06
PT1641787E (pt) 2007-08-01
CN101597282A (zh) 2009-12-09
PL1641787T3 (pl) 2007-08-31
JP2009513484A (ja) 2009-04-02
US8357685B2 (en) 2013-01-22
EP1641787B1 (en) 2007-05-02
EG24929A (en) 2011-01-05
KR20060024440A (ko) 2006-03-16
DE602004006268T2 (de) 2008-01-10
HRP20070286T3 (en) 2007-08-31
DE602004006268D1 (de) 2007-06-14
IS8248A (is) 2006-01-20
TW200524917A (en) 2005-08-01
CA2530310A1 (en) 2005-01-06
KR101131378B1 (ko) 2012-04-04
US8071594B2 (en) 2011-12-06
US20070149524A1 (en) 2007-06-28
RU2006101859A (ru) 2006-06-10
US20150105387A1 (en) 2015-04-16
CY1107703T1 (el) 2013-04-18
IL172529A (en) 2011-06-30
US9452169B2 (en) 2016-09-27
BRPI0411729A (pt) 2006-08-08
US20160074413A1 (en) 2016-03-17
IS2463B (is) 2008-11-15

Similar Documents

Publication Publication Date Title
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
ATE418924T1 (de) Marknagel
DK1472255T3 (da) Aza-arylpiperaziner
IS2463B (is) Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE462365T1 (de) Marknagel
NO20054225D0 (no) Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister
ATE375761T1 (de) Marknagel
NO20053598D0 (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
ATE514681T1 (de) N-substituierte pyrazolylcarboxanilide
DK1633719T3 (da) Substituerede spirobenzazepiner
DE50311770D1 (de) Oberfräse
FR2852619B1 (fr) Echafaudage volant
DE60315718D1 (de) Ventrikuläre pulsraten-stabilisation
SE0301314L (sv) Klammer
ES1066792Y (es) Grapa
SE0302332D0 (sv) New use I
NO20031983D0 (no) Brannslukning
DOS2003000768S (es) Dispersador
FI20031730A0 (fi) Halkaisukirves
SE0301797D0 (sv) New use V
SE0300106D0 (sv) New use
ITRE20020026A1 (it) Zanzariera
FI5342U1 (fi) Vaatekaappi